OPSENS AWARDED CONTRACT BY MAJOR U.S. GROUP PURCHASING ORGANIZATION OptoWire gains access to more than 50 PCI centers Quebec City, Quebec, October 14, 2020 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company commercializing a second-generation fiber optic pressure guidewire to diagnose and treat coronary disease, announced today it has been awarded a […]
Category: News & Events
OpSens to Present at Lytham Partners Virtual Investor Growth Conference
Quebec City, Quebec, September 30, 2020 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering diagnostic and treatment solutions based on its proprietary optical technology, will participate in a virtual presentation and fireside chat at the October 2020 Lytham Partners Virtual Investor Growth Conference on Tuesday, October 6, 2020 […]
OPSENS TO PRESENT AT THE LD 500 VIRTUAL CONFERENCE
OPSENS TO PRESENT AT THE LD 500 VIRTUAL CONFERENCE Quebec City, Quebec, August 26, 2020 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a Company focusing mainly on physiological measurements in interventional cardiology, today announced it will be presenting at the LD 500 investor conference on Tuesday, September 1st at 10:20 AM Eastern Time (7:20 AM Pacific […]
OpSens Releases Q3 Results
OPSENS ANNOUNCES RESULT FOR Q3 2020 Quebec City, Quebec, July 15, 2020 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) today reported its results for the third quarter of 2020. Highlights Net earnings of $0.1 M for the third quarter ended May 31, 2020 compared with a net loss of $1.1 M for the corresponding […]
Opsens – 100,000 Cases Performed with the OptoWire
Opsens – 100,000 cases performed with the OptoWire Quebec City, Quebec, May 20, 2020 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) reached an important milestone with more than 100,000 patients evaluated with the OptoWire™, a pressure guidewire for the diagnosis and treatment of coronary artery stenosis. Accuracy in assessing the severity of coronary disease […]
The Financial Post: How is OpSens improving cardiovascular disease treatment?
The Financial Post released a piece based on this week’s interview on OpSens’ C-Suite at the Open, a series highlighting the stories of companies listed on the TSX. Link to Financial Post piece […]
OpSens at C-Suite at the Open
TORONTO, April 27, 2020 /CNW/ https://www.youtube.com/watch?v=i7qXYFwhH8g The C-Suite At the Open video interview series highlights the unique perspectives of listed companies on Toronto Stock Exchange and TSX Venture Exchange. Videos provide insight into how company executives think in the current business environment. To see the latest C-Suite At The Open videos visit http://www.newswire.ca/en/releases/archive/April2020/27/c0533.html. About OpSens Inc. (TSX:OPS) OpSens focuses […]
OPSENS ANNOUNCES Q2 2020 RESULTS
OPSENS ANNOUNCES Q2 2020 RESULTS Quebec City, Quebec, April 9, 2020 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) today reported its results for the second quarter of 2020. Highlights OpSens continues operations and adjusts to face the COVID-19 crisis; Consolidated product sales totaled $8.3 M in the second quarter of 2020 compared with […]
OPSENS PROVIDES OPERATIONAL UPDATE – Continues to supply essential cardiovascular solutions to patients around the world
OPSENS PROVIDES OPERATIONAL UPDATE Continues to supply essential cardiovascular solutions to patients around the world Quebec City, Quebec, March 24, 2020 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a cardiology-focused company delivering diagnostic and treatment solutions based on its proprietary optical technology, today provided a business update in light of recent action taken […]
